新股消息 | 礼邦医药拟港股IPO 中国证监会要求说明是否计划继续推进A股上市及具体安排

Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas issuance and listing, specifically requesting details from Libang Pharmaceutical regarding its previous listing on the Jiangsu Equity Exchange and the reasons for its termination [1] - Libang Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with Jefferies, BofA Securities, and HTSC acting as joint sponsors [1] - The CSRC requires Libang Pharmaceutical to clarify the situation of its major shareholders and any significant impacts on the current issuance and listing process [1] Group 2 - The company must provide detailed explanations regarding its equity structure, including past capital increases and share transfer pricing, to ensure compliance with legal regulations [2] - The company is required to clarify the reasons for any capital reductions and the payment situations involved, ensuring that there are no issues of false capital contributions or tax compliance [2] - The company must also disclose the circumstances surrounding its employee stock ownership plan, including the rationale for any pricing discrepancies and compliance with relevant regulations [3] Group 3 - Libang Pharmaceutical is a leading global biopharmaceutical company focused on kidney disease, with a comprehensive portfolio of innovative products and a significant market potential valued in the hundreds of billions of dollars [3] - The company has established a vertically integrated platform that encompasses research and development, production, and commercialization [3]